SK30298A3 - Cell-cycle checkpoint genes - Google Patents

Cell-cycle checkpoint genes Download PDF

Info

Publication number
SK30298A3
SK30298A3 SK302-98A SK30298A SK30298A3 SK 30298 A3 SK30298 A3 SK 30298A3 SK 30298 A SK30298 A SK 30298A SK 30298 A3 SK30298 A3 SK 30298A3
Authority
SK
Slovakia
Prior art keywords
polypeptide
rad3
atr
protein
seq
Prior art date
Application number
SK302-98A
Other languages
English (en)
Slovak (sk)
Inventor
Anthony Michael Carr
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icos Corp filed Critical Icos Corp
Publication of SK30298A3 publication Critical patent/SK30298A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SK302-98A 1995-09-06 1996-09-06 Cell-cycle checkpoint genes SK30298A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9518220.0A GB9518220D0 (en) 1995-09-06 1995-09-06 Checkpoint gene
CZ1998656A CZ292808B6 (cs) 1995-09-06 1996-09-06 ATR polypeptid, polynukleotid, který jej kóduje, způsoby jejich detekce, vektor a protilátka
PCT/GB1996/002197 WO1997009433A1 (en) 1995-09-06 1996-09-06 Cell-cycle checkpoint genes

Publications (1)

Publication Number Publication Date
SK30298A3 true SK30298A3 (en) 2000-04-10

Family

ID=25746866

Family Applications (1)

Application Number Title Priority Date Filing Date
SK302-98A SK30298A3 (en) 1995-09-06 1996-09-06 Cell-cycle checkpoint genes

Country Status (13)

Country Link
EP (1) EP0856058B1 (xx)
JP (1) JPH11511984A (xx)
CN (1) CN1201492A (xx)
AU (1) AU730220B2 (xx)
BR (1) BR9610168A (xx)
CA (1) CA2231190A1 (xx)
CZ (1) CZ292808B6 (xx)
GB (1) GB9518220D0 (xx)
IL (1) IL123553A0 (xx)
NO (1) NO980957L (xx)
PL (1) PL325427A1 (xx)
SK (1) SK30298A3 (xx)
WO (1) WO1997009433A1 (xx)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997018323A2 (en) * 1995-11-16 1997-05-22 Icos Corporation Cell-cycle checkpoint phosphatidylinositol- (pik-) related kinases, genes coding therefor and methods for assaying and modulating enzymatic activity
GB9718952D0 (en) * 1997-09-05 1997-11-12 Medical Res Council Mammalian chk1 effector cell cycle checkpoint protein kinase materials and methods
ATE331791T1 (de) 1998-02-23 2006-07-15 Icos Corp Phosphodiesterase 10
US6479256B1 (en) 1998-03-04 2002-11-12 Icos Corporation Lectomedin materials and methods
US6071691A (en) * 1998-04-27 2000-06-06 Oregon Health Science University Materials and methods for modulating differentiation
US6790950B2 (en) 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
KR20060116041A (ko) 1999-04-09 2006-11-13 파마시아 앤드 업존 캄파니 엘엘씨 항균성 백신 조성물
US6670167B1 (en) * 1999-11-01 2003-12-30 Agouron Pharmaceuticals, Inc. Catalytic domain of the human effector cell cycle checkpoint protein kinase materials and methods for identification of inhibitors thereof
US6344549B1 (en) 1999-10-14 2002-02-05 Icos Corporation ATR-2 cell cycle checkpoint
WO2001031005A2 (en) 1999-10-22 2001-05-03 Pharmacia & Upjohn Company Drosophila g protein coupled receptors, nucleic acids, and methods related to the same
CA2390078A1 (en) 1999-11-24 2001-05-31 David E. Lowery G protein-coupled receptor-like receptors and modulators thereof
US6498026B2 (en) 2000-02-25 2002-12-24 Hercules Incorporated Variant galactose oxidase, nucleic acid encoding same, and methods of using same
US6734005B2 (en) 2000-05-22 2004-05-11 Pharmacia & Upjohn Company Matrix metalloproteinases
US6686449B2 (en) 2000-06-30 2004-02-03 Pharmacia & Upjohn Company Mutant presenilin 1 polypeptides
WO2002002639A2 (en) 2000-07-05 2002-01-10 Pharmacia & Upjohn Company Human ion channels
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US7098007B2 (en) 2001-08-22 2006-08-29 California Institute Of Technology Cloning and functional assays of Xenopus ATR
CA2475768A1 (en) * 2002-02-13 2003-08-21 University Of Rochester Methods of inhibiting hiv-1 vpr activity and hiv-1 infectivity using atr or rad17 inhibitors
EP1572106B1 (en) 2002-11-15 2010-05-05 Novartis Vaccines and Diagnostics, Inc. Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
WO2004070062A2 (en) * 2003-02-04 2004-08-19 Wyeth Compositions and methods for diagnosing and treating cancers
US7541158B2 (en) 2004-04-14 2009-06-02 Monell Chemical Senses Center Taste receptors of the T1R family from domestic dog
WO2005116063A1 (en) 2004-05-24 2005-12-08 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Live, oral vaccine for protection against shigella dysenteriae serotype 1
US20060134698A1 (en) 2004-12-20 2006-06-22 Evanston Northwestern Healthcare Research Institute Methods for treating cardiac disease by modifying an N-terminal domain of troponin I
PT2298815E (pt) 2005-07-25 2015-07-16 Emergent Product Dev Seattle Moléculas de ligaçao especificas para cd37 e especificas para cd20
JP5580535B2 (ja) 2006-01-05 2014-08-27 ノバルティス アーゲー 癌転移および癌転移に関連する骨量減少を予防および処置するための方法
MX2008015524A (es) 2006-06-12 2009-01-13 Trubion Pharmaceuticals Inc Proteinas de union multivalentes monocatenarias con funcion efectora.
WO2009047567A1 (en) * 2007-10-10 2009-04-16 University Of Sheffield Assay for identifying agents which inhibit the atr and/or dna-pk pathways
WO2009126944A1 (en) 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
ES2657220T3 (es) 2008-10-02 2018-03-02 Aptevo Research And Development Llc Proteínas de unión multi-diana antagonistas de CD86
EP2516467A2 (en) 2009-12-23 2012-10-31 Emergent Product Development Seattle, LLC Compositions comprising tnf-alpha and il-6 antagonists and methods of use thereof
ME02505B (me) 2009-12-29 2017-02-20 Aptevo Res & Development Llc Heterodimerni vezujući proteini i njihove upotrebe
RU2447899C2 (ru) 2010-05-27 2012-04-20 Михаил Валентинович Филатов Композиция для лечения гепатита с и способ лечения гепатита с
MY172692A (en) 2012-07-13 2019-12-10 Calysta Inc Biorefinery system, methods and compositions thereof
MY173663A (en) 2012-11-09 2020-02-14 Calysta Inc Compositions and methods for biological production of fatty acid derivatives
WO2014205146A1 (en) 2013-06-18 2014-12-24 Calysta, Inc. Compositions and methods for biological production of lactate from c1 compounds using lactate dehydrogenase transformants
DK3027204T3 (da) 2013-07-29 2022-04-19 2Seventy Bio Inc Flerdelte signaleringsproteiner og anvendelser deraf
SG11201605423UA (en) 2014-01-02 2016-07-28 Trelys Inc Compositions and methods for biological production of amino acids in hydrogenotrophic microorganisms
CN105916976A (zh) 2014-01-16 2016-08-31 凯利斯塔公司 碳水化合物富集的重组微生物
WO2015120334A2 (en) 2014-02-07 2015-08-13 Effector Therapeutics, Inc. Compositions and methods for treating neurological disorders
WO2015120350A2 (en) 2014-02-07 2015-08-13 Effector Therapeutics, Inc. Compositions and methods for treating fibrotic disease
JP2017510297A (ja) 2014-03-17 2017-04-13 タピミューン インコーポレイテッド 核酸分子ワクチン組成物およびその使用
KR20170008255A (ko) 2014-05-15 2017-01-23 칼리스타, 인코포레이티드 초장 탄소쇄 화합물의 생물학적 생성 방법
WO2016022400A1 (en) 2014-08-04 2016-02-11 Fred Hutchinson Cancer Research Center T cell immunotherapy specific for wt-1
EP3212223B1 (en) 2014-10-27 2021-08-18 Fred Hutchinson Cancer Research Center Compositions and methods for boosting the efficacy of adoptive cellular immunotherapy
SG11201708741YA (en) 2015-05-06 2017-11-29 Trelys Inc Compositions and methods for biological production of methionine
WO2016187486A1 (en) 2015-05-19 2016-11-24 Fred Hutchinson Cancer Research Center Biomarkers and uses thereof for selecting pancreas cancer intervention
MY197562A (en) 2015-09-21 2023-06-23 Aptevo Res & Development Llc Cd3 binding polypeptides
WO2017112944A1 (en) 2015-12-23 2017-06-29 Fred Hutchinson Cancer Research Center High affinity t cell receptors and uses thereof
US20170191136A1 (en) 2015-12-31 2017-07-06 Effector Therapeutics, Inc. Mnk biomarkers and uses thereof
EP3402878A1 (en) 2016-01-11 2018-11-21 Zoetis Services LLC Novel cross protective vaccine compositions for porcine epidemic diarrhea virus
CA3022267A1 (en) 2016-05-04 2017-11-09 Fred Hutchinson Cancer Research Center Cell-based neoantigen vaccines and uses thereof
WO2017193104A1 (en) 2016-05-06 2017-11-09 Fred Hutchinson Cancer Research Center T-cell immunotherapy specific for mart-1
CN109996868A (zh) 2016-09-23 2019-07-09 弗雷德哈钦森癌症研究中心 特异性用于次要组织相容性(h)抗原ha-1的tcr及其用途
CA3035080A1 (en) 2016-09-27 2018-04-05 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules
US11534461B2 (en) 2016-11-14 2022-12-27 Fred Hutchinson Cancer Center High affinity merkel cell polyomavirus T antigen-specific TCRS and uses thereof
CN110072547B (zh) 2016-12-14 2024-04-30 硕腾服务有限责任公司 断奶前对抗欧洲猪繁殖与呼吸综合征(prrs)病毒株的有效疫苗接种
WO2018148567A1 (en) 2017-02-09 2018-08-16 Fred Hutchinson Cancer Research Center Biomarkers and uses thereof for selecting immunotherapy intervention
AU2018234830B2 (en) 2017-03-15 2023-03-02 Fred Hutchinson Cancer Center High affinity MAGE-A1-specific TCRs and uses thereof
CA3064000A1 (en) 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy
CA3070272A1 (en) 2017-07-20 2019-01-24 Aptevo Research And Development Llc Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
WO2019055862A1 (en) 2017-09-14 2019-03-21 Fred Hutchinson Cancer Research Center HIGH AFFINITY T CELL RECEPTORS AND USES THEREOF
AU2018341244A1 (en) 2017-09-26 2020-03-05 Cero Therapeutics, Inc. Chimeric engulfment receptor molecules and methods of use
WO2019109047A1 (en) 2017-12-01 2019-06-06 Fred Hutchinson Cancer Research Center Binding proteins specific for 5t4 and uses thereof
SG11202005692WA (en) 2017-12-20 2020-07-29 Harbour Biomed Shanghai Co Ltd Antibodies binding ctla-4 and uses thereof
WO2019140278A1 (en) 2018-01-11 2019-07-18 Fred Hutchinson Cancer Research Center Immunotherapy targeting core binding factor antigens
JP2021512637A (ja) 2018-02-12 2021-05-20 フレッド ハッチンソン キャンサー リサーチ センター サイクリンａ１特異的ｔ細胞受容体およびその使用
AU2019224051A1 (en) 2018-02-26 2020-09-03 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
US20210024607A1 (en) 2018-03-28 2021-01-28 Cero Therapeutics, Inc. Expression vectors for chimeric engulfment receptors, genetically modified host cells, and uses thereof
WO2019191332A1 (en) 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Chimeric engulfment receptors and uses thereof for neurodegenerative diseases
EP3774865A1 (en) 2018-03-28 2021-02-17 Cero Therapeutics, Inc. Cellular immunotherapy compositions and uses thereof
WO2019191334A1 (en) 2018-03-28 2019-10-03 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
WO2019232479A2 (en) 2018-06-01 2019-12-05 Fred Hutchinson Cancer Research Center Biomarkers, uses thereof for selecting immunotherapy intervention, and immunotherapy methods
WO2020139974A1 (en) 2018-12-27 2020-07-02 Calysta, Inc. Glycogen-null methanotrophs and uses thereof
CN114026116A (zh) 2019-02-20 2022-02-08 弗雷德哈钦森癌症研究中心 Ras新抗原特异性结合蛋白及其用途
CA3132845A1 (en) 2019-03-11 2020-09-17 Fred Hutchinson Cancer Research Center High avidity wt1 t cell receptors and uses thereof
CN114555790A (zh) 2019-08-20 2022-05-27 弗雷德哈钦森癌症研究中心 Wt-1特异性t细胞免疫疗法
EP4038097A1 (en) 2019-10-03 2022-08-10 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof
BR112022013725A2 (pt) 2020-01-13 2022-10-11 Aptevo Res & Development Llc Formulações para agentes terapêuticos proteicos
BR112022013730A2 (pt) 2020-01-13 2022-10-11 Aptevo Res & Development Llc Métodos e composições para prevenir a adsorção de proteínas terapêuticas aos componentes do sistema de distribuição de drogas
US11376320B2 (en) 2020-03-05 2022-07-05 Iowa State University Research Foundation, Inc. Immunogenic and vaccine compositions against SARS-CoV-2
WO2022036287A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Anti-cd72 chimeric receptors and uses thereof
WO2022036265A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Chimeric tim receptors and uses thereof
WO2022036285A1 (en) 2020-08-14 2022-02-17 Cero Therapeutics, Inc. Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase
WO2022066965A2 (en) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunotherapy targeting sox2 antigens
WO2022066973A1 (en) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunotherapy targeting pbk or oip5 antigens
WO2022072431A1 (en) 2020-09-30 2022-04-07 Zoetis Services Llc Novel pasteurella multocida strains and vaccines having hyac and nanp deletions
TW202222841A (zh) 2020-10-06 2022-06-16 福瑞德哈金森腫瘤研究中心 用於治療表現mage-a1之疾病的組成物及方法
KR20230160242A (ko) 2021-02-26 2023-11-23 켈로니아 테라퓨틱스, 인코포레이티드 림프구 표적화된 렌티바이러스 벡터
CN115216451A (zh) 2021-04-16 2022-10-21 硕腾服务有限责任公司 伪狂犬病病毒疫苗
JP2024519964A (ja) 2021-05-21 2024-05-21 アプティーボ リサーチ アンド デベロップメント エルエルシー タンパク質治療薬のための投薬レジメン
WO2023010097A1 (en) 2021-07-28 2023-02-02 Cero Therapeutics, Inc. Chimeric tim4 receptors and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997018323A2 (en) * 1995-11-16 1997-05-22 Icos Corporation Cell-cycle checkpoint phosphatidylinositol- (pik-) related kinases, genes coding therefor and methods for assaying and modulating enzymatic activity

Also Published As

Publication number Publication date
NO980957D0 (no) 1998-03-05
NO980957L (no) 1998-05-05
IL123553A0 (en) 1998-10-30
CZ292808B6 (cs) 2003-12-17
AU730220B2 (en) 2001-03-01
EP0856058B1 (en) 2006-07-26
CN1201492A (zh) 1998-12-09
WO1997009433A1 (en) 1997-03-13
PL325427A1 (en) 1998-07-20
CA2231190A1 (en) 1997-03-13
JPH11511984A (ja) 1999-10-19
AU6884696A (en) 1997-03-27
CZ65698A3 (cs) 2000-01-12
BR9610168A (pt) 1998-08-11
EP0856058A1 (en) 1998-08-05
GB9518220D0 (en) 1995-11-08

Similar Documents

Publication Publication Date Title
EP0856058B1 (en) Cell-cycle checkpoint genes
CA2119443C (en) Human cyclin e
JP3091769B2 (ja) プロテインキナーゼ
US6218136B1 (en) Methods of the identification of pharmaceutically active compounds
JP4418103B2 (ja) 新規なヒトチェックポイントキナーゼ、ｈＣＤＳ１、組成物および方法
WO1998020030A2 (en) DISRUPTION OF THE MAMMALIAN Rad51 PROTEIN AND DISRUPTION OF PROTEINS THAT ASSOCIATE WITH MAMMALIAN Rad51 FOR HINDERING CELL PROLIFERATION
US20030077262A1 (en) Methods and compositions for modulating apoptosis
EP0690874B1 (en) Materials and methods relating to proteins that interact with casein kinase i
US7049395B2 (en) Anti-inflammatory compounds and uses thereof
JP2005040137A (ja) Ｊｎｋを標的化することによりプログラム細胞死またはアポトーシスをブロックする新規な因子の同定
US6218515B1 (en) Cyclin E variants and use thereof
EP1263939B1 (en) 18477, a human protein kinase and uses therefor
JP2001510684A (ja) アッセイ、治療法及び治療手段
JPH07505057A (ja) プロテインキナーゼ
US6632936B2 (en) Cell-cycle checkpoint genes
US20060205020A1 (en) Cell-cycle checkpoint genes
RU2252256C2 (ru) ГОМОЛОГИ (ATR) ПОЛИПЕПТИДА rad3, ПОЛИНУКЛЕОТИДЫ И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И МАТЕРИАЛЫ
JP2001508868A (ja) 細胞ｄｎａ 修復活性の調節に関するアッセイ、剤、治療及び診断
AU676137C (en) Human cyclin E
US6365372B1 (en) SNF2 related CBP activator protein (SRCAP)
JP2003503069A (ja) 新規キナーゼおよびその使用
US20060057669A1 (en) Inactive transcription factor tif-ia and uses thereof
MXPA98001699A (en) Control point genes of the celu cycle